Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path. Trading volume reached 209.3 million shares, about 1,000% above its three-month average of 19.1 million shares. ImmunityBio IPO'd in 2015 and has fallen 81% since going public. How the markets moved today ...